Eltanexor

DB16153InvestigationalSmall molecule

Eltanexor is under investigation in clinical trial NCT02649790 (Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/refractory Cancer Indications).

Formula / weight: C₁₇H₁₀F₆N₆O · 428.298 g/mol (avg)
Code names: KPT-8602

Resolves to

Compound

UNIIQ59IQJ9NTKCAS1642300-52-4ChEMBLCHEMBL4297623

Structure

InChIKeyJFBAVWVBLRIWHM-AWNIVKPZSA-NSMILESNC(=O)C(=C\N1C=NC(=N1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)\C1=CN=CN=C1

Targets

O14980XPO1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Eltanexor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account